Page last updated: 2024-09-03

gefitinib and t0901317

gefitinib has been researched along with t0901317 in 3 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(t0901317)
Trials
(t0901317)
Recent Studies (post-2010) (t0901317)
5,2315662,9195673330

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)t0901317 (IC50)
Chain A, Oxysterols receptor LXR-betaHomo sapiens (human)0.1
Chain A, Oxysterols receptor LXR-betaHomo sapiens (human)0.1
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)0.0386
Nuclear receptor ROR-alphaHomo sapiens (human)2.3
Presenilin-1Homo sapiens (human)4.5
Presenilin-2Homo sapiens (human)4.5
Nuclear receptor ROR-gammaHomo sapiens (human)1.6113
Oxysterols receptor LXR-betaHomo sapiens (human)0.4688
Oxysterols receptor LXR-alphaHomo sapiens (human)0.0223
Gamma-secretase subunit APH-1BHomo sapiens (human)4.5
NicastrinHomo sapiens (human)4.5
Nuclear receptor ROR-betaHomo sapiens (human)10
Gamma-secretase subunit APH-1AHomo sapiens (human)4.5
Bile acid receptorHomo sapiens (human)5.3
Gamma-secretase subunit PEN-2Homo sapiens (human)4.5

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ1
Cao, H; Ding, L; Feng, J; Li, H; Liu, S; Ma, R; Ni, J; Wang, Z; Wu, J; Zhang, XQ; Zhao, X; Zhou, LL1
Cao, H; Dong, S; Feng, J; Lou, R; Ma, R; Shi, C; Wu, J; Xu, X1

Other Studies

3 other study(ies) available for gefitinib and t0901317

ArticleYear
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
    Biochemical and biophysical research communications, 2014, May-09, Volume: 447, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones

2014
Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.
    Cancer medicine, 2018, Volume: 7, Issue:5

    Topics: Adenocarcinoma of Lung; ATP Binding Cassette Transporter 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; PPAR gamma; Sulfonamides; Thiazolidinediones

2018
Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro.
    Anti-cancer drugs, 2019, Volume: 30, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Female; Gefitinib; Humans; Hydrocarbons, Fluorinated; In Vitro Techniques; Liver X Receptors; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019